Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Schmitz

Showing results (331-340 of 385) with videos related to

Pageof 39
Sort By:
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
International Journal of Cancer|June 15, 2017
TP53 mutation and survival in aggressive B cell lymphomaThorsten Zenz, Markus Kreuz, Maxi Fuge, et al.
Cancers|November 26, 2022
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World ScenarioCarolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
Blood|January 22, 2013
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphomaHeike Horn, Marita Ziepert, Claudia Becher, et al.
Blood Advances|January 30, 2023
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysisCatherine Thieblemont, Bettina Altmann, Fabian Frontzek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaChristian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.
Hemasphere|December 8, 2022
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA TrialFriederike Braulke, Florian Zettl, Marita Ziepert, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2015
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITDAnthony D Ho, Johannes Schetelig, Tilmann Bochtler, et al.
The Lancet. Haematology|February 3, 2022
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, et al.
Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.
Pageof 39

Showing results (331-340 of 385) with videos related to

Sort By:
Pageof 39
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
International Journal of Cancer|June 15, 2017
TP53 mutation and survival in aggressive B cell lymphomaThorsten Zenz, Markus Kreuz, Maxi Fuge, et al.
Cancers|November 26, 2022
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World ScenarioCarolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
Blood|January 22, 2013
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphomaHeike Horn, Marita Ziepert, Claudia Becher, et al.
Blood Advances|January 30, 2023
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysisCatherine Thieblemont, Bettina Altmann, Fabian Frontzek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaChristian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.
Hemasphere|December 8, 2022
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA TrialFriederike Braulke, Florian Zettl, Marita Ziepert, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2015
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITDAnthony D Ho, Johannes Schetelig, Tilmann Bochtler, et al.
The Lancet. Haematology|February 3, 2022
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, et al.
Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.
Pageof 39